Isotretinoin is the go-to prescription for treatment of acne vulgaris, but ocular morbidities like dry eye disease and blepharoconjunctivitis are common due to the drug’s shrinking of oil glands. Patients and dermatologists may not be aware of these side effects or their prevalence. Faculty will look at clinical studies and discuss the best methods to counteract ocular adverse events, so that patients and practitioners alike will see the big picture.

Facial redness, bumps, flushing—it may seem that rosacea is all out in the open. But in this session Faculty will examine the less noticed, the conditions dermatologists often miss in their diagnoses. Neurogenic rosacea, rosacea fulminans, and rosacea blepharitis will be discussed, as well as other comorbidities.

Clearing up any misconceptions, Faculty will look at the latest findings regarding topical and oral treatments for the two most common and chronic skin conditions. Which treatments are looking best in 2025? What advances have been made? Can both oral and topical treatments be used together, harmoniously, or is utopia far off?

An expert-led Q&A and panel discussion focused on acne and rosacea

Neuromodulators are botulinum toxin injections used to treat wrinkles—you may know them by their popular names. We will discuss what’s new, what’s old, what’s FDA approved, what’s off label, and what’s best for particular cosmetic needs.

Treating skin of color with energy-based modalities comes with unique challenges, notably increased risk of scarring and post-inflammatory hyperpigmentation. Unfamiliarity with proper technique remains common. This session will clear up misconceptions by discussing how to select the proper tools, wavelengths, and procedures to treat patients of color.

Oral tranexamic acid, originally used to lessen menstrual bleeding, has shown efficacy in reducing hyperpigmentation disorders. Faculty will examine the clinical evidence behind this treatment and discuss who might be best suited for this approach. Future studies and current limitations will be considered.

An expert-led Q&A and panel discussion focused on cosmetic dermatology and laser treatments

PDE4 inhibitors are an emerging treatment for common inflammatory skin diseases. By targeting the enzyme that produces cytokines, PDE4 inhibitors decrease inflammation. Faculty will discuss in detail this process and review the benefits and drawbacks of current treatments.

Patients with psoriasis may be up to 50% more likely to develop cardiovascular (CV) disease than patients without. A holistic approach to treatment that includes routine CV screening and risk assessment is necessary. Faculty will explain how inflammation leads to heart attack and stroke, examine recent studies, and consider whether managing one lowers the risk of the other.

An expert-led Q&A and panel discussion exploring psoriasis

Supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, both are Johnson and Johnson companies.

Overactivity of the EGFR protein is a key factor in certain cancer developments. While EGFR inhibitors can effectively slow this process, they often cause skin-related adverse events that can severely affect a patient’s quality of life and their willingness to stick to treatment. Faculty will illustrate how dermatologists are positioned to play integral roles in non-skin cancer treatment by managing dermatological toxicities.

Beauty is more than skin deep—it affects our self-confidence and mental health. Skin conditions like eczema and psoriasis react to emotional states. This session holds the mirror up to psychodermatological disorders to get a clear picture of the skin/mind connection.

An increasing amount of research suggests a significant link between the skin and gut, both large microbiomes. In addition, inflammation affects joint health. Faculty will examine how all three are connected.

Obesity is a systemic disease that involves multiple organs, including the skin. Around 60-70% of obese patients present with dermatological changes. These commonly include skin tags, psoriasis, hidradenitis suppurativa, atopic dermatitis, and increased risk of skin infections. Anti-obesity medications may also cause adverse skin reactions. Practitioners will learn how to navigate this complicated, multi-faceted condition.

An expert-led Q&A and panel discussion exploring interdisciplinary approaches in dermatology

Pollution, allergens, bacteria, sun—all the things our skin acts as barrier to in turn affects our skin, giving rise to various atopic conditions. Faculty will discuss environmental exposures and their link to skin disorders. Various treatment regimens be examined.

Faculty will review the four main pathologies of itch. Due to limited effective medications on the market, novel treatments and new clinical trials will be surveyed to ascertain whether any herald a revelation.

This session is aimed at pediatricians and primary-care physicians, often the first healthcare workers to see young patients. Common causes of rash will be discussed. Treatments for eczema, a chronic skin condition that affects up to 20% of children in the US, will be reviewed. Faculty will advise how to mitigate quality of life issues by taking a multidisciplinary approach to care.

An expert-led Q&A and panel discussion focused on itch and atopic dermatitis management

Alopecia areata (AA) is an autoimmune disorder that triggers hair loss. Due to its cosmetic nature, AA is often accompanied by psychological distress in patients. This session will help untangle the complex relations between the genetic, environmental, and immune-related factors behind AA. Faculty will weigh various treatment options and discuss diagnostic approaches.

Just a freckle? Melanoma has a 99% 5-year survival rate if caught in its earliest stage (also called melanoma in situ). Practitioners will learn how to successfully identify melanoma, when to recommend screening in patients, and how to treat this relatively common cancer—at any stage.

Mohs surgery is the removal of skin layer by layer until there is no indication of cancer. Often the best treatment for certain basal- and squamous-cell carcinomas, it is also cost-effective and efficient. Faculty will illustrate best surgical practices and discuss when to recommend this treatment.

The Seal of Recommendation is given to products that meet the Skin Cancer Foundation’s criteria for effective sun protection. Attendees will discover how that criteria is selected and what updates were made in 2025. As skin cancer is the most common type of cancer, this session is a must for PCPs and specialists alike.

An expert-led Q&A and panel discussion focused on dermatologic surgery and skin cancer care